Download PDF
Dtsch Med Wochenschr 2004; 129(24): 1390-1394
DOI: 10.1055/s-2004-826876
Kommentare
Osteologie / Rheumatologie
© Georg Thieme Verlag Stuttgart · New York

Wachstumshormon, Knochenstoffwechsel und Osteoporose beim Erwachsenen

Growth hormone, bone metabolism and osteoporosis in adulthoodP. H. Kann1
  • 1Endokrinologie & Diabetologie, Universität Marburg
Further Information

Publication History

eingereicht: 19.11.2003

akzeptiert: 18.3.2004

Publication Date:
21 July 2004 (online)

Also available at
    Permissions and Reprints

Glossar

GH: Wachstumshormon

IGF: Insulin-ähnlicher Wachstumsfaktor (IGF-1 wurde früher als Somatomedin C bezeichnet)

IGFBP: Bindungsprotein für Insulin-ähnliche Wachstumsfaktoren

Literatur

  • 1 Abrahamsen B, Hangaard J, Horn H C, Hansen T B, Gregersen G, Hansen-Nord M. et al . Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies.  Clin Endocrinol. 2002;  57 273-281
    Google Scholar
  • 2 Ahmad A M, Thomas J, Clewes A, Hopkins M T, Guzder R, Ibrahim H. et al . Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism.  J Clin Endocrinol Metab. 2003;  88 2860-2868
    Google Scholar
  • 3 Aloia J F, Zanzi I, Ellis K, Jowsey J, Roginsky M, Wallach S, Cohn S H. Effects of growth hormone in osteoporosis.  J Clin Endocrinol Metab. 1976;  43 992-999
    Google Scholar
  • 4 Aloia J F, Vaswani A, Kapoor A, Yeh J K, Cohn S H. Treatment of osteoporosis with calcitonin, with and without growth hormone.  Metabolism. 1985;  34 124-129
    Google Scholar
  • 5 Aloia J F, Vaswani A, Meunier P J, Edouard C M, Arlot M E, Yeh J K, Cohn S H. Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin.  Calcif Tissue Int. 1987;  40 253-259
    Google Scholar
  • 6 Amato G, Carella C, Fazio S, LaMontagna G, Cittadini A, Sabatini D. et al . A Body composition, body metabolism and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses.  J Clin Endocrinol Metab. 1993;  77 1671-1676
    Google Scholar
  • 7 Amato G, Izzo G, La Montagna G, Bellastella A. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects.  Clin Endocrinol. 1996;  45 27-32
    Google Scholar
  • 8 Balducci R, Toscano V, Pasquino A M, Mangiantini A, Municchi G, Armenise P. et al . Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy.  Eur J Endocrinol. 1995;  132 42-46
    Google Scholar
  • 9 Baroncelli G I, Bertelloni S, Sodini F, Saggese G. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height: timing and peak values for lumbar BMD.  Clin Endocrinol. 2004;  60 175-184
    Google Scholar
  • 10 Baum H B, Biller B M, Finkelstein J S, Cannistraro K B, Oppenhein D S, Schoenfeld D A. et al . Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial.  Ann Intern Med. 1996;  125 883-890
    Google Scholar
  • 11 Beshyah S A, Kyd P, Thomas E, Fairney A, Johnston D G. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults.  Clin Endocrinol. 1995;  42 249-254
    Google Scholar
  • 12 Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial.  J Bone Miner Res. 2002;  17 1081-1094
    Google Scholar
  • 13 Bing-You R G, Denis M C, Rosen C J. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone response to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3.  Calcif Tissue Int. 1993;  52 183-187
    Google Scholar
  • 14 Brill K T, Weltman A L, Gentili A, Patrie J T, Fryburg D A, Hanks J B. et al . Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men.  J Clin Endocrinol Metab. 2002;  87 5649-5657
    Google Scholar
  • 15 Brixen K, Kassem M, Eriksen E F, Nielsen H K, Flyvbjerg A, Mosekilde L. Growth hormone (GH) and adult bone remodelling: the potential use of GH in treatment of osteoporosis.  J Pediatr Endocrinol. 1993;  6 65-71
    Google Scholar
  • 16 De Boer H, Blok G J, van Lingen A, Teule G J, Lips P, van der Veen E A. Consequences of childhood-onset growth hormone deficiency for adult bone mass.  J Bone Miner Res. 1994;  9 1319-1326
    Google Scholar
  • 17 Degerblad M, Elgindy N, Hall K, Sjöberg H -E, Thoren M. Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism.  Acta Endocrinol. 1992;  126 387-393
    Google Scholar
  • 18 Degerblad M, Bengtsson B A, Bramnert M, Johnell O, Manhem P, Rosen T, Thoren M. Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy.  Eur J Endocrinol. 1995;  133 180-188
    Google Scholar
  • 19 Dennison E M, Hindmarsh P C, Kellingray S, Fall C H, Cooper C. Growth hormone predicts bone density in elderly women.  Bone. 2003;  32 434-440
    Google Scholar
  • 20 Dequeker J, Burssens A, Boullion R. Dynamics of growth hormone secretion in patients with osteoporosis and in patients with osteoarthrosis.  Horm Res. 1982;  16 353-356
    Google Scholar
  • 21 Elgindy N, Grunditz R, Thoren M, Degerblad M, Sjöberg H E, Ringertz H. Longterm follow-up of metacarpal cortical thickness and bone mineral density in panhypopituitarism.  Radiol Diag. 1991;  32 326-330
    Google Scholar
  • 22 Erdtsieck R J, Pols H A, Valk N K, van Ouwerkerk B M, Lamberts S W, Mulder P, Birkenhager J C. Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controled trial.  Clin Endocrinol. 1995;  43 557-565
    Google Scholar
  • 23 Eriksen E F, Kassem M, Brixen K. Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis.  Horm Res. 1993;  40 95-98
    Google Scholar
  • 24 Ernst M, Froesch E R. Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor I.  Biochem Biophys Res Commun. 1988;  151 142-147
    Google Scholar
  • 25 Finkenstedt G, Gasser R W, Hofle G, Watfah C, Fridrich L. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up.  Eur J Endocrinol. 1997;  136 282-289
    Google Scholar
  • 26 Franco P, Marelli O, Lattuada D, Locatelli V, Cocchi D, Muller E E. Influence of growth hormone on the immunosuppressive effect of prednisolone in mice.  Acta Endocrinol Copenh. 1990;  123 339-344
    Google Scholar
  • 27 Gillberg P, Johansson A G, Blum W F, Groth T, Ljunghall S. Growth hormone secretion and sensitivity in men with idiopathic osteoporosis.  Calcif Tissue Int. 2001;  68 67-73
    Google Scholar
  • 28 Gillberg P, Mallmin H, Petren-Mallmin M, Ljunghall S, Nilsson A G. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis.  J Clin Endocrinol Metab. 2002;  87 4900-4906
    Google Scholar
  • 29 Giovannucci E, Pollak M, Platz E A, Willett W C, Stampfer M J, Majeed N. et al . Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses’ Health Study.  Growth Horm IGF Res. 2000;  10 S30-S31 (Suppl A)
    Google Scholar
  • 30 Giustina A, Bussi A R, Jacobello C, Wehrenberg W B. Effects of recombinant growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucorticoid treatment with suppressed endogenous GH response to GH-releasing hormone.  J Clin Endocrinol Metab. 1995;  80 122-129
    Google Scholar
  • 31 Gomez J M, Gomez N, Fiter J, Soler J. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement.  Horm Metab Res. 2000;  32 66-70
    Google Scholar
  • 32 Gonnelli S, Cepollaro C, Montomoli M, Gennari L, Montagnani A, Palmierei R, Gennari C. Treatment of postmenopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.  Clin Endocrinol. 1997;  46 55-61
    Google Scholar
  • 33 Hansen T B, Brixen K, Vahl N, Jorgensen J O, Christiansen J S, Mosekilde L, Hagen C. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study.  J Clin Endocrinol Metab. 1996;  81 3352-3359
    Google Scholar
  • 34 Holmes S J, Economou G, Whitehouse R W, Adams J E, Shalet S M. Reduced bone mineral density in patients with adult-onset growth hormone deficiency.  J Clin Endocrinol Metab. 1994;  78 669-674
    Google Scholar
  • 35 Holmes S J, Whitehouse R W, Swindell R, Economou G, Adams J E, Shalet S M. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency.  Clin Endocrinol. 1995;  42 627-633
    Google Scholar
  • 36 Johannsson G, Rosen T, Bosacus I, Sjöström L, Bengtsson B -A. Two years growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency.  J Clin Endocrinol Metab. 1996;  81 2865-2873
    Google Scholar
  • 37 Johansson A G, Lindh E, Blum W F, Kollerup G, Sorensen O H, Ljunghall S J. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis.  Clin Endocrinol Metab. 1996;  81 44-48
    Google Scholar
  • 38 Johansson A G, Eriksen E F, Lindh E, Langdahl B, Blum W F, Lindahl A. et al . Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men.  J Clin Endocrinol Metab. 1997;  82 2795-2798
    Google Scholar
  • 39 Kann P, Piepkorn B, Schehler B, Piepenburg R, Lotz J, Bockisch A. et al . Replacement therapy with recombinant human growth hormone (GH) in GH-deficient adults: effects on bone metabolism and bone mineral density in a 2-year prospective study.  Endocrinol Metab. 1995;  2 103-110
    Google Scholar
  • 40 Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults.  Clin Endocrinol. 1998;  48 561-568
    Google Scholar
  • 41 Kann P H. Growth Hormone in Anti-Aging Medicine: A Critical Review.  Aging Male. 2003;  6 257-263
    Google Scholar
  • 42 Kassem M, Brixen K, Blum W, Mosekilde I, Eriksen E F. No evidence for reduced spontaneous or growth hormone stimulated serum levels of insulin-like growth factor (IGF)-1, IGP-II or IGF binding protein 3 in women with spinal osteoporosis.  Eur J Endocrinol. 1994;  131 150-155
    Google Scholar
  • 43 Kassem M, Brixen K, Mosekilde I, Eriksen E F. Human marrow stromal osteoblast-like cells do not show reduced responsiveness to in vitro stimulation with growth hormone in patients with postmenopausal osteoporosis.  Calcif Tissue Int. 1994;  54 1-6
    Google Scholar
  • 44 Kassem M, Brixen K, Blum W, Mosekilde I, Eriksen E F. Normal osteoclastic and osteoblastic response to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.  J Bone Miner Res. 1994;  9 1365-1370
    Google Scholar
  • 45 Kaufman J M, Taelman P, Vermeulen A, Vandeweghe M. Bone mineral status in growth hormone deficient males with isolated and multiple pituitary deficiencies of childhood onset.  J Clin Endocrinol Metab. 1992;  74 118-123
    Google Scholar
  • 46 Kruse H P, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone.  Horm Metab Res. 1975;  7 488-491
    Google Scholar
  • 47 Kurland B S, Chan P K, Rosen C J, Bilezikian J P. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I.  J Clin Endocrinol Metab. 1998;  83 2576-2579
    Google Scholar
  • 48 Li G, Zeng M. Relation of serum growth hormone and estradiol levels and osteoporosis in postmenopausal women.  Chung Hua Tsa Chin Taipei. 1990;  70 16-19
    Google Scholar
  • 49 Maor G, Hochberg Z, Von der Murk K, Heinegard D, Silberman M M. Human growth hormone enhances chondrogenesis and osteogenesis in a tissue culture system of chondro-progenitor cells.  Endocrinol. 1992;  125 1239-1245
    Google Scholar
  • 50 Mucci L A, Tamimi R, Lagiou P, Trichopoulou A, Benetou V, Spanos E, Trichopoulos D. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system?.  BJU Int. 2001;  87 814-20
    Google Scholar
  • 51 Nishiyama K, Sugimoto T, Kaji H, Kanatani M, Kobayashi T, Chihara K. Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation.  Endocrinol. 1996;  137 35-41
    Google Scholar
  • 52 Oertl H, Strasburger C J, Kann P, Quabbe H J. Empfehlungen zur Indikation und Durchführung einer Wachstumshormon-Substitution im Erwachsenenalter.  Dtsch Med Wochenschr. 1998;  123 883-886
    Google Scholar
  • 53 Ohlsson C, Bengtsson B A, Isaksson O G, Andreassen T T, Slootweg M C. Growth Hormone and bone.  Endocr Rev. 1998;  10 55-79
    Google Scholar
  • 54 Ortoft G, Oxlund H. Qualitative alterations of cortical bone in female rats after long-term administration of growth hormone and glucocorticoid.  Bone. 1996;  18 581-590
    Google Scholar
  • 55 Ott S M, Aitken M L. Osteoporosis in patients with cystic fibrosis.  Clin Chest Med. 1998;  19 555-567
    Google Scholar
  • 56 Papanicolaou D A, Wilder R L, Manolagos S C, Chrousos G P. The pathophysiologic roles of interleukin-6 in human disease.  Ann Intern Med. 1998;  128 127-137
    Google Scholar
  • 57 Rico H, Del-Rio A, Vila T, Patino R, Carrera F, Espinos D. The role of growth hormone in the pathogenesis of postmenopausal osteoporosis.  Arch Intern Med. 1979;  139 1263-1265
    Google Scholar
  • 58 Rosé n T, Hansson T, Granhed H, Szucs J, Bengtsson B -A. Reduced bone mineral content in adult patients with growth hormone deficiency.  Acta Endocrinol. 1993;  129 201-206
    Google Scholar
  • 59 Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Lindstedt G, Wilske J, Bengtsson B A. Increased fracture rate in adults with growth hormone deficiency.  Endocrinol Metab. 1996;  3 121
    Google Scholar
  • 60 Rubin C D. Southwestern internal medicine conference: growth hormone - aging and osteoporosis.  Am J Med Sci. 1993;  305 120-129
    Google Scholar
  • 61 Rudman D, Feller A G, Nagraj H S, Gergans G A, Lalitha P Y, Goldberg A F, Mattson D E. et al . Effects of human growth hormone in men over 60 years old.  N Engl J Med. 1990;  323 1-6
    Google Scholar
  • 62 Saaf M, Hilding A, Thoren M, Troell S, Hall K. Growth hormone treatment of osteoporotic postmenopausal women - a one year placebo-controlled study.  Eur J Endocrinol. 1999;  140 390-399
    Google Scholar
  • 63 Sartorio A, Conti A, Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency.  Postgraduate Med J. 1993;  69 846-850
    Google Scholar
  • 64 Shalet S M, Shavrikova E, Cromer M, Child C J, Keller E, Zapletalova J. et al . Effect of Growth Hormone (GH) Treatment on Bone in Postpubertal GH-deficient Patients: A 2-Year Randomized, Controlled, Dose-Ranging Study.  J Clin Endocrinol Metab. 2003;  88 4124-4129
    Google Scholar
  • 65 Shaneyfelt T, Husein R, Bubley G, Mantzoros C S. Hormonal predictors of prostate cancer: a meta-analysis.  J Clin Oncol. 2000;  18 847-853
    Google Scholar
  • 66 Slootweg M C, van Buul-Offers S C, Herrmann-Erlec M PM, van der Meer J M, Duursma S A. Growth hormone is mitogenic for fetal mouse osteoblasts but not for undifferentiated bone cells.  J Endocrinol. 1988;  116 R11-R13
    Google Scholar
  • 67 Sneppen S B, Hoeck H C, Kollerup G, Sorensen O H, Laurberg P, Feldt-Rasmussen U. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults - an 18-month randomised, placebo-controlled, double blinded trial.  Eur J Endocrinol. 2002;  146 187-195
    Google Scholar
  • 68 Stracke H, Schulz A, Moeller D, Rossol S, Schatz H. Effect of growth hormone on osteoblasts and demonstration of somatomedin-C IGF-1 in bone organ culture.  Acta Endocrinol. 1984;  107 16-24
    Google Scholar
  • 69 Strasburger C J, Schopohl J, Kann P, Oertel H. Diagnostische Kriterien für die Indikation zur Wachstumshormonsubstitution bei Erwachsenen.  Dtsch Med Wochenschr. 1997;  112 861-863
    Google Scholar
  • 70 Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K. Effect of recombinant human growth hormone in elderly osteoporotic women.  Clin Endocrinol. 1999;  51 715-724
    Google Scholar
  • 71 Sugimoto T, Kaji H, Nakaoka D, Yamauchi M, Yano S, Sugishita T. et al . Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis.  Eur J Endocrinol. 2002;  147 339-348
    Google Scholar
  • 72 Swolin-Eide D, Nilsson A, Ohlsson C. Cortisol increases growth hormone-receptor expression in human osteoblast-like cells.  J Endocrinol. 1998;  156 99-105
    Google Scholar
  • 73 Tanaka H, Seino Y. Does growth hormone treatment prevent corticosteroid-induced osteoporosis?.  Bone. 1996;  18 493-494
    Google Scholar
  • 74 Vandeweghe M, Taelman P, Kaufman J M. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males.  Clin Endocrinol. 1993;  39 409-415
    Google Scholar
  • 75 Wüster C, Slenczka E, Ziegler R. Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?.  Klin Wochenschr. 1991;  69 769-773
    Google Scholar
  • 76 Wüster C, Abs R, Bengtsson B A, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E. et al . The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density.  J Bone Miner Res. 2001;  16 398-405
    Google Scholar

Prof. Dr. med. Peter Herbert Kann

Leiter des Bereichs Endokrinologie & Diabetologie, Klinikum der Philipps-Universität Marburg

35033 Marburg

Phone: 06421/2863135

Fax: 06421/2862733

Email: kannp@med.uni-marburg.de

      >